Mirogabalin and reboxetine in the treatment of chronic pain

Łukasz Pawlak; Dominik Kurant; Michał Graczyk; Jarosław Woroń

doi:10.5114/mp.2025.148747

eISSN: 2081-2833
ISSN: 2081-0016

Medycyna Paliatywna/Palliative Medicine

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

1/2025
vol. 17

Send email

Copy url:

abstract:

Guidelines/recommendations

Mirogabalin and reboxetine in the treatment of chronic pain

Łukasz Pawlak

¹

,

Dominik Kurant

¹

,

Michał Graczyk

¹

,

Jarosław Woroń

^{2, 3}

Katedra Opieki Paliatywnej, Collegium Medicum w Bydgoszczy, Uniwersytet Mikołaja Kopernika w Toruniu, Bydgoszcz, Polska
Zakład Farmakologii Klinicznej, Katedra Farmakologii, Wydział Lekarski, Collegium Medicum Uniwersytet Jagielloński, Kraków, Polska
Kliniczny Oddział Anestezjologii i Intensywnej Terapii, Szpital Uniwersytecki, Kraków, Polska

Medycyna Paliatywna 2025; 17(1): 21–26

DOI: https://doi.org/10.5114/mp.2025.148747

Online publish date: 2025/04/02

View full text Get citation

PlumX metrics:

Despite the wide range of drugs used in the pharmacotherapy of chronic pain, new substances are still being sought that perform as effectively or better than currently known analgesics. The analgesic effects of drugs that are already used in therapy for indications other than pain are also being sought. A new drug from the gabapentinoid group, mirogabalin, and reboxetine – an antidepressant from the selective norepinephrine reuptake inhibitor group are showing promise in the treatment of chronic pain, particularly neuropathic pain. This article provides a narrative review of the scientific reports published to date in this area using the aforementioned substances.

keywords:

Mirogabalin and reboxetine in the treatment of chronic pain

Łukasz Pawlak 1 , Dominik Kurant 1 , Michał Graczyk 1 , Jarosław Woroń 2, 3

chronic pain, neuropathic pain, mirogabalin, reboxetine

Łukasz Pawlak

¹

,

Dominik Kurant

¹

,

Michał Graczyk

¹

,

Jarosław Woroń

^{2, 3}